DISULFIRAM

Post-LOE

disulfiram

Molecular Devices

ANDAORALTABLET

Approved

Mar 2011

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

5/8 — Partial

DISULFIRAM (disulfiram) by Molecular Devices is acetyl aldehyde dehydrogenase inhibitors [moa]. Approved for aldehyde dehydrogenase inhibitor [epc]. First approved in 2011.

Drug data last refreshed 20h ago

$0.0BPart D

Mechanism of Action

Acetyl Aldehyde Dehydrogenase Inhibitors

Pharmacologic Class:

Aldehyde Dehydrogenase Inhibitor

Indications

Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.

Clinical Trials (7)

NCT05667415N/ANot Yet Recruiting

Treatment of Advance Gastric Cancer With Disulfiram

Started Jun 2023

40 enrolled

Chemotherapy；Advanced Gastric Cancer；Cisplatin；Disulfiram

NCT04521335Phase 1Terminated

Study of Disulfiram and Copper Gluconate in Patients With Treatment-Refractory Multiple Myeloma

Started May 2021

2 enrolled

Multiple Myeloma

NCT03714555Phase 2Terminated

Disulfiram-Copper Gluconate in Met Pancreas Cancer w Rising CA19-9 on Abraxane-Gemzar, FOLFIRINOX or Gemcitabine

Started Oct 2019

1 enrolled

Metastatic Pancreatic Cancer

NCT03198559Phase 1/2Terminated

Combination Latency Reversal With High Dose Disulfiram Plus Vorinostat in HIV-infected Individuals on ART

Started Aug 2017

5 enrolled

HIV Infections

NCT02963051Phase 1Terminated

A Phase Ib Study of Intravenous Copper Loading With Oral Disulfiram in Metastatic, Castration Resistant Prostate Cancer

Started Jul 2017

9 enrolled

Prostate Cancer

Worked on DISULFIRAM at Molecular Devices? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.